Nicholas Hoffman & Company LLC. Sells 118 Shares of Johnson & Johnson (NYSE:JNJ)

Nicholas Hoffman & Company LLC. lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,697 shares of the company’s stock after selling 118 shares during the period. Johnson & Johnson makes up about 1.7% of Nicholas Hoffman & Company LLC.’s holdings, making the stock its 13th biggest position. Nicholas Hoffman & Company LLC.’s holdings in Johnson & Johnson were worth $5,529,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. American Money Management LLC boosted its stake in shares of Johnson & Johnson by 2.5% in the 2nd quarter. American Money Management LLC now owns 32,369 shares of the company’s stock valued at $4,508,000 after purchasing an additional 795 shares in the last quarter. GAM Holding AG raised its stake in Johnson & Johnson by 11.1% during the 2nd quarter. GAM Holding AG now owns 153,285 shares of the company’s stock worth $21,349,000 after acquiring an additional 15,290 shares during the period. Tiverton Asset Management LLC raised its position in shares of Johnson & Johnson by 20.7% during the second quarter. Tiverton Asset Management LLC now owns 210,447 shares of the company’s stock valued at $29,311,000 after buying an additional 36,041 shares during the last quarter. Pekin Hardy Strauss Inc. increased its position in Johnson & Johnson by 0.3% in the second quarter. Pekin Hardy Strauss Inc. now owns 37,143 shares of the company’s stock worth $5,173,000 after purchasing an additional 100 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in Johnson & Johnson by 71.7% in the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 18,194 shares of the company’s stock worth $2,534,000 after purchasing an additional 7,595 shares during the last quarter. 72.12% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE JNJ traded down $0.32 during mid-day trading on Friday, reaching $130.11. 1,656,706 shares of the company were exchanged, compared to its average volume of 7,701,360. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $341.90 billion, a PE ratio of 15.91, a PEG ratio of 2.19 and a beta of 0.68. The company’s 50 day moving average price is $130.11 and its 200 day moving average price is $135.97.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.42 by $0.16. The firm had revenue of $20.56 billion during the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.10 earnings per share. On average, sell-side analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date of this dividend was Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

Several research analysts have commented on JNJ shares. Goldman Sachs Group set a $169.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a report on Thursday, July 18th. Bank of America reiterated a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Barclays started coverage on Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 price target on the stock. Finally, Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $150.60.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Marijuana Stocks

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.